Type 1 Diabetes Mellitus

Quick Reference

Critical Alerts

• Absolute insulin deficiency is life-threatening: T1DM is fatal without exogenous insulin; NEVER stop insulin even when fasting or unwell
• DKA develops rapidly (4-6 hours): Especially with pump failure or missed doses; mortality 0.5-2% in adults [1]
• Sick day rules are life-saving: Never stop insulin during illness; check ketones every 2-4 hours; increase insulin by 20-50%
• Hypoglycemia requires immediate treatment: Rule of 15 (15g fast-acting carbs, recheck at 15 min); severe hypoglycemia requires glucagon/IV dextrose
• HbA1c target less than 53 mmol/mol (7%): Associated with 60% reduction in microvascular complications (DCCT) [2]
• Autoantibodies confirm diagnosis: GAD65, IA-2, ZnT8 antibodies; distinguish from Type 2 in atypical presentations
• Technology transforms outcomes: CGM + insulin pump (hybrid closed-loop) improves time-in-range and reduces hypoglycemia [3]

Classic Presentation

Emergency Treatments

---

Definition

Overview

Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disease characterized by T-cell-mediated destruction of pancreatic beta-cells in the islets of Langerhans, resulting in absolute insulin deficiency. [5,6] Unlike Type 2 diabetes, which is primarily driven by insulin resistance with relative insulin deficiency, T1DM results from near-complete loss of endogenous insulin production, making lifelong exogenous insulin therapy essential for survival.

The disease was uniformly fatal before the discovery of insulin by Banting and Best in 1921 at the University of Toronto. [7] Modern management has evolved from survival to optimization, with the goal of mimicking physiological insulin secretion using basal-bolus regimens, continuous subcutaneous insulin infusion (CSII/pumps), and increasingly, automated insulin delivery systems (hybrid closed-loop). [8]

T1DM accounts for approximately 5-10% of all diabetes cases but represents the majority of diabetes diagnosed in childhood and adolescence. However, it can present at any age, and approximately 50% of T1DM cases are diagnosed after age 20. [9] Late-onset autoimmune diabetes in adults (LADA, sometimes termed "Type 1.5 diabetes") represents a slowly progressive form with features overlapping Type 1 and Type 2 diabetes. [10]

Classification

By Etiology (ADA/WHO Classification):

By Stage of Development [11]:

Epidemiology

Global Incidence and Prevalence:

• Prevalence: Approximately 9 million people worldwide have T1DM [12]
• Proportion: 5-10% of all diabetes cases
• Incidence: Highly variable geographically (0.1-60 per 100,000/year)
• Annual increase: Global incidence increasing by 3-4% per year, especially in children less than 5 years [13]

Demographics:

• Age of onset:
  • "Bimodal peaks: 4-6 years and 10-14 years"
  • 50% diagnosed before age 18
  • 50% diagnosed after age 20 (often misdiagnosed as Type 2)
• Sex distribution: Slight male predominance after puberty (M:F ratio ~1.3:1)
• Ethnic variation: Higher incidence in Caucasian populations; lower in East Asian populations

Geographic Variation [14]:

The remarkable geographic variation suggests environmental factors interact with genetic susceptibility.

---

Etiology and Pathophysiology

Genetic Susceptibility

HLA Associations [15,16]: The major histocompatibility complex (MHC) on chromosome 6p21, specifically HLA class II genes, accounts for approximately 50% of genetic risk for T1DM.

Non-HLA Genetic Factors:

• INS gene (VNTR): Insulin gene polymorphisms on chromosome 11
• PTPN22: Lymphoid tyrosine phosphatase (T-cell activation)
• IL2RA: Interleukin-2 receptor alpha (regulatory T-cells)
• CTLA4: Cytotoxic T-lymphocyte antigen 4 (T-cell regulation)
• IFIH1: Interferon-induced helicase (viral response)

Genetic Risk Summary:

• General population risk: 0.4%
• Sibling of affected individual: 6-7%
• Offspring of affected mother: 2-3%
• Offspring of affected father: 6-7% (paternal transmission paradox)
• Identical twin concordance: 30-50% (proves environmental factors are essential)

Environmental Triggers

Viral Triggers [17]:

Other Environmental Factors:

• Early infant diet: Early cow's milk exposure (inconsistent evidence); early gluten introduction
• Vitamin D deficiency: Lower vitamin D levels associated with increased risk
• Gut microbiome: Reduced microbial diversity precedes T1DM development
• Hygiene hypothesis: Reduced early microbial exposure may impair immune tolerance
• Geographic latitude: Higher incidence at higher latitudes (less UV exposure/vitamin D)

Immunopathogenesis

The Autoimmune Cascade [5,6,18]:

Stage 1: Genetic Susceptibility + Environmental Trigger

• HLA class II molecules present beta-cell autoantigens to CD4+ T-helper cells
• Environmental triggers (viral infection, dietary factors) initiate or accelerate the process
• Loss of central and peripheral tolerance to beta-cell antigens

Stage 2: Insulitis (Silent Phase)

• CD8+ cytotoxic T-lymphocytes infiltrate islets of Langerhans
• CD4+ T-helper cells (Th1 phenotype) secrete pro-inflammatory cytokines (IFN-gamma, TNF-alpha, IL-1beta)
• Macrophages and dendritic cells contribute to inflammatory milieu
• Autoantibodies appear (markers, not primary effectors)
• Progressive beta-cell destruction occurs over months to years
• Glucose tolerance remains normal while > 80% beta-cell mass remains

Stage 3: Clinical Diabetes

• Symptoms appear when > 80-90% of beta-cell mass is destroyed
• Absolute insulin deficiency leads to hyperglycemia and ketosis
• Remaining beta-cells may transiently recover with insulin therapy ("honeymoon phase")

Autoantibodies

Islet Autoantibodies as Diagnostic Markers [19]:

Prognostic Significance:

• ≥2 autoantibodies positive: > 90% will develop clinical T1DM within 15 years [11]
• Number of antibodies: More antibodies = faster progression
• Age at seroconversion: Younger age = faster progression

Metabolic Consequences of Insulin Deficiency

The Triad of Metabolic Derangement:

1. Carbohydrate Metabolism:

   • Decreased glucose uptake by muscle and adipose tissue (GLUT4-mediated)
   • Increased hepatic glucose production (gluconeogenesis, glycogenolysis)
   • Hyperglycemia → osmotic diuresis → dehydration → electrolyte losses

2. Fat Metabolism:

   • Uninhibited lipolysis in adipose tissue (hormone-sensitive lipase)
   • Free fatty acids released to liver
   • Hepatic ketogenesis (acetoacetate, beta-hydroxybutyrate, acetone)
   • Ketoacidosis when ketone production exceeds utilization

3. Protein Metabolism:

   • Increased proteolysis (muscle wasting)
   • Amino acids diverted to gluconeogenesis
   • Negative nitrogen balance

The Counter-Regulatory Response: In insulin deficiency, counter-regulatory hormones are unopposed:

• Glucagon: Increased hepatic glucose output, ketogenesis
• Cortisol: Gluconeogenesis, protein catabolism, insulin resistance
• Growth hormone: Lipolysis, insulin resistance
• Catecholamines: Glycogenolysis, lipolysis, gluconeogenesis

---

Clinical Presentation

Symptoms

Classic Symptoms (Developing Over Days to Weeks):

"The 4 T's" (Public Health Awareness Campaign):

• Toilet (polyuria, bed-wetting)
• Thirsty (polydipsia)
• Tired (fatigue)
• Thinner (weight loss)

DKA at Presentation [4]:

• 25-30% of new T1DM diagnoses present with diabetic ketoacidosis
• Higher rates in:
  • "Younger children (less than 2 years): up to 50%"
  • Ethnic minorities (delayed diagnosis)
  • Lower socioeconomic status
  • Areas with lower T1DM incidence (lower awareness)

History

Key Diagnostic Questions:

1. Symptom Onset and Duration:

   • How long have you had these symptoms? (Days to weeks suggests T1DM)
   • Has there been any weight loss? How much?
   • Any bed-wetting (children) or nocturia?

2. Associated Symptoms (DKA):

   • Any nausea, vomiting, or abdominal pain?
   • Any fruity or sweet smell to your breath?
   • Any difficulty breathing or rapid breathing?
   • Any confusion or drowsiness?

3. Risk Factors:

   • Family history of Type 1 diabetes or autoimmune diseases?
   • Personal history of other autoimmune conditions (thyroid, celiac, vitiligo)?
   • Recent viral illness? (may trigger onset)

4. Distinguishing from Type 2:

   • Age of onset (young suggests T1DM, but can occur at any age)
   • BMI (usually normal in T1DM; often elevated in T2DM)
   • Rapidity of symptom onset (acute in T1DM; insidious in T2DM)
   • Family history (stronger for T2DM in first-degree relatives)
   • Ketosis at presentation (highly suggestive of T1DM)

Physical Examination

At Presentation (New Diagnosis):

Established T1DM (Annual Review):

---

Red Flags and Emergency Presentations

Diabetic Ketoacidosis (DKA)

Definition and Diagnosis [20]:

DKA Severity Classification:

Precipitating Factors [1]:

DKA Management Protocol [21]:

"FIG-PICK" Mnemonic:

• Fluids: 0.9% saline 1L stat over 1 hour, then slower (avoid rapid correction → cerebral edema)
• Insulin: Fixed-rate IV insulin 0.1 units/kg/hour
• Glucose: Add 10% dextrose when blood glucose less than 14 mmol/L (to allow continued insulin for ketone clearance)
• Potassium: Add K+ to fluids if K+ less than 5.5 mmol/L (insulin drives K+ intracellularly)
• Infection: Identify and treat precipitating cause
• Chart: Hourly monitoring of glucose, ketones, K+, pH
• Ketones: Treatment endpoint is ketone resolution (less than 0.6 mmol/L), NOT glucose normalization

Critical Points:

• Continue fixed-rate insulin until ketones less than 0.6 mmol/L AND pH > 7.3 AND bicarbonate > 18 mmol/L
• Overlap SC insulin with IV insulin by at least 30 minutes before stopping IV
• DO NOT stop long-acting (basal) insulin during DKA management

Severe Hypoglycemia

Definition: Hypoglycemia requiring assistance from another person for treatment [22]

Classification:

Symptoms by Category:

Hypoglycemia Unawareness [23]:

• Definition: Reduced ability to perceive warning symptoms of hypoglycemia
• Prevalence: 20-40% of T1DM patients with long duration
• Mechanism: Recurrent hypoglycemia downregulates counter-regulatory response; autonomic symptoms blunted
• Diagnosis:
  • Clarke or Gold questionnaires
  • HYPO score assessment
• Management:
  • Strict avoidance of hypoglycemia for 2-3 weeks can restore awareness
  • CGM with low glucose alerts
  • Relaxed glycemic targets
  • Consider insulin pump/hybrid closed-loop

Treatment of Hypoglycemia:

"Rule of 15" (Conscious Patient):

1. Give 15-20g fast-acting carbohydrate:
   • 3-4 glucose tablets
   • 150-200 mL fruit juice or regular soda
   • 4-5 jelly babies
   • Glucose gel (GlucoGel)
2. Wait 15 minutes, recheck blood glucose
3. Repeat if glucose still less than 4.0 mmol/L
4. Once glucose > 4.0 mmol/L, follow with long-acting carbohydrate (if next meal not imminent)

Severe Hypoglycemia (Unconscious/Unable to Swallow):

• Glucagon: 1 mg IM/SC (or nasal glucagon if available)
• IV Dextrose: 75-100 mL of 20% dextrose (or 150-200 mL of 10%)
• Place in recovery position
• Nothing by mouth until fully conscious
• Identify and address cause

---

Differential Diagnosis

Distinguishing T1DM from T2DM

Other Considerations

---

Diagnostic Approach

Diagnostic Criteria [24]

Diabetes Diagnosis (Any ONE of the following):

Confirming Type 1 (vs Type 2):

Laboratory Investigations

At Diagnosis:

Annual Monitoring (Established T1DM):

---

Treatment

Principles of Insulin Therapy

Goals of Treatment:

1. Glycemic targets:
   • HbA1c less than 53 mmol/mol (7%) for most adults
   • Time-in-range (TIR) > 70% (3.9-10.0 mmol/L) with CGM
   • Minimize hypoglycemia (less than 4% time below 3.9 mmol/L)
2. Prevent acute complications: DKA, severe hypoglycemia
3. Prevent chronic complications: Retinopathy, nephropathy, neuropathy, cardiovascular disease
4. Maintain quality of life: Flexibility, minimal burden

Insulin Regimens

Basal-Bolus Therapy (Multiple Daily Injections, MDI) [25]:

The Gold Standard for Intensive Therapy:

Basal Insulin Options:

Bolus (Rapid-Acting) Insulin Options:

Calculating Insulin Doses:

1. Total Daily Dose (TDD): 0.5-1.0 units/kg/day (average 0.5-0.7 for adults)

   • Lower in newly diagnosed (honeymoon phase)
   • Higher with obesity, puberty, illness, steroids

2. Basal:Bolus Split: Typically 40-50% basal, 50-60% bolus

3. Insulin-to-Carbohydrate Ratio (ICR):

   • Starting estimate: 500 ÷ TDD = grams of carbohydrate covered by 1 unit
   • Example: TDD = 50 units → ICR = 1:10 (1 unit per 10g carbs)
   • Individualize based on glucose response

4. Insulin Sensitivity Factor (ISF/Correction Factor):

   • Starting estimate: 100 ÷ TDD = glucose drop (mmol/L) per 1 unit
   • Example: TDD = 50 units → ISF = 2 (1 unit lowers glucose by 2 mmol/L)
   • Individualize based on glucose response

Continuous Subcutaneous Insulin Infusion (CSII) - Insulin Pumps

Mechanism: Delivers only rapid-acting insulin continuously via subcutaneous cannula [26]

• Basal rate: Programmable hourly rates (can vary throughout day)
• Bolus: User-activated for meals and corrections

Advantages over MDI:

• More precise basal delivery
• Variable basal rates (address dawn phenomenon)
• Easier management of exercise, shift work
• More precise bolus dosing (0.05-0.1 unit increments)
• Reduced injection burden
• Bolus calculators integrated

Disadvantages:

• Cost (device, consumables)
• Technical complexity
• Risk of rapid DKA if pump fails (no long-acting insulin on board)
• Cannula site infections
• Must be worn continuously

Indications (NICE NG17) [27]:

• Recurrent severe hypoglycemia
• Hypoglycemia unawareness
• Suboptimal HbA1c despite MDI
• Significant dawn phenomenon
• Needle phobia
• Quality of life considerations
• Pregnancy (or planning pregnancy)

Pump Failure Protocol: If glucose > 14 mmol/L with ketones on pump:

1. Assume pump/cannula failure
2. Give correction dose by pen injection immediately
3. Change infusion set and cannula
4. Troubleshoot pump later
5. If ketones rising, treat as DKA

Hybrid Closed-Loop Systems (Automated Insulin Delivery)

"Artificial Pancreas" Technology [3,8,28]:

Components:

1. CGM sensor: Continuous glucose monitoring (every 5 minutes)
2. Insulin pump: Delivers insulin subcutaneously
3. Algorithm: Automated adjustment of basal insulin delivery based on CGM glucose

Types of Systems:

Available Systems (UK):

Benefits (NICE TA943 recommends HCL for T1DM) [29]:

• Improved time-in-range (typically 70-80%)
• Reduced hypoglycemia (especially nocturnal)
• Improved HbA1c (0.3-0.5% reduction vs MDI/standard pump)
• Reduced glycemic variability
• Improved quality of life
• Reduced diabetes distress

Continuous Glucose Monitoring (CGM)

Types of CGM [30]:

Key CGM Metrics:

CGM is now Standard of Care: NICE recommends CGM for all T1DM adults [27]

Structured Education

DAFNE (Dose Adjustment for Normal Eating) [31]:

• Evidence-based structured education program
• Teaches flexible insulin dosing based on carbohydrate counting
• 5-day course (or equivalent)
• Key skills:
  • Carbohydrate counting and estimation
  • Insulin-to-carb ratios and correction factors
  • Pattern management
  • Sick day rules
  • Hypoglycemia management
  • Exercise adjustments

Injection Technique

Best Practice:

Lipohypertrophy:

• Fatty lumps at injection sites from repeated injections in same area
• Causes erratic insulin absorption → unexplained glucose variability
• Prevention: Strict site rotation; inspect sites at every clinic visit
• Treatment: Avoid affected areas; lumps often resolve over months

---

Special Situations

Sick Day Rules [32]

The Golden Rule: NEVER STOP INSULIN DURING ILLNESS

Even if not eating, basal insulin is essential to prevent ketogenesis.

Sick Day Traffic Light System:

Sick Day Management:

1. Monitor frequently: Blood glucose every 2-4 hours; ketones every 4 hours
2. Maintain hydration: 100-200 mL sugar-free fluids per hour
3. Continue basal insulin: Never reduce or omit
4. Adjust bolus insulin:
   • If eating less: reduce mealtime bolus proportionally
   • If glucose elevated: increase correction doses
5. Extra insulin for ketones: 10-20% of total daily dose as rapid-acting
6. Seek medical help if:
   • Ketones > 3.0 mmol/L
   • Unable to keep fluids down
   • Symptoms of DKA (vomiting, abdominal pain, drowsiness, Kussmaul breathing)
   • Glucose persistently > 20 mmol/L despite extra insulin
   • Uncertain what to do

Exercise and Sport

Physiological Responses [33]:

Exercise Guidelines:

1. Pre-exercise:

   • Check blood glucose
   • If less than 5 mmol/L: consume 15-30g carbs before starting
   • If > 14 mmol/L with ketones > 1.5: do not exercise until resolved
   • Consider reducing bolus by 25-75% for meal before exercise

2. During exercise:

   • Consume 15-30g carbs per 30-60 min of activity (if prolonged aerobic)
   • Monitor for hypoglycemia symptoms

3. Post-exercise:

   • Risk of delayed hypoglycemia (up to 24 hours, especially nocturnal)
   • Consider reducing evening basal by 10-20%
   • Have carbohydrate snack before bed if late exercise
   • CGM alerts particularly valuable

Alcohol

The Alcohol-Hypoglycemia Connection [34]:

• Alcohol inhibits hepatic gluconeogenesis
• Risk of delayed hypoglycemia (4-24 hours after drinking)
• Glucagon is ineffective when liver is metabolizing alcohol
• Symptoms of hypoglycemia may be confused with intoxication

Safe Drinking Guidelines:

1. Never drink on an empty stomach
2. Consume carbohydrate with alcohol
3. Do not bolus fully for alcohol (low/no carbs in spirits)
4. Eat carbohydrate snack before bed
5. Reduce overnight basal if on pump
6. Set alarms to check glucose overnight
7. Do not exercise after drinking (compounds hypoglycemia risk)

Pregnancy

Pre-Conception [35]:

Risks with Suboptimal Control:

• Congenital malformations (cardiac, neural tube defects, sacral agenesis)
• Miscarriage
• Macrosomia
• Pre-eclampsia
• Preterm delivery
• Stillbirth

Pregnancy Management:

Intrapartum:

• Variable rate IV insulin infusion (VRIII) during labor
• Hourly glucose monitoring
• Aim for glucose 4-7 mmol/L
• Immediate reduction of insulin after delivery (placenta removal removes insulin resistance)

Driving (DVLA Regulations UK) [36]

Group 1 License (Car/Motorcycle):

• Must notify DVLA if on insulin
• Must have awareness of hypoglycemia
• No severe hypoglycemia requiring third-party assistance in past 12 months
• Blood glucose testing required before driving and every 2 hours on long journeys
• Do not drive if glucose less than 5 mmol/L (treat and wait 45 minutes)
• Carry fast-acting glucose in vehicle

Group 2 License (HGV/Bus):

• Stricter requirements; must meet additional medical standards
• Regular specialist review required
• CGM with alarms may be acceptable

If Severe Hypoglycemia While Driving:

• License revoked (typically 1 year)
• Must meet standards before reinstatement

Perioperative Management [37]

Elective Surgery:

VRIII (Sliding Scale):

• Continuous IV infusion of short-acting insulin
• Adjust rate based on hourly blood glucose
• Co-infuse 5-10% dextrose + potassium
• Continue basal (Lantus/Levemir/Tresiba) unless major surgery
• Overlap SC insulin with VRIII for at least 30-60 minutes before discontinuing

Key Principles:

• First on morning operating list
• Never omit basal insulin (prevents DKA)
• Monitor glucose every 1-2 hours perioperatively
• Target glucose 6-10 mmol/L
• Resume usual regimen when eating and drinking normally

Travel

Preparation:

• Carry letter from healthcare provider confirming diabetes and need for insulin/supplies
• Ensure adequate travel insurance covering diabetes
• Carry 2-3 times usual supplies (anticipate delays)
• Insulin in carry-on luggage (hold luggage may freeze)

Time Zone Changes:

Storage:

• Insulin stable at room temperature for 28 days (in use)
• Avoid extremes: do not freeze; avoid direct sunlight/heat
• Frio cooling cases for hot climates

Airport Security:

• Declare diabetes supplies
• Insulin pumps and CGMs should not go through X-ray; request hand search
• Carry prescription/letter for customs

---

Chronic Complications

Microvascular Complications

Driven by Duration and Glycemic Control: Risk reduced by 60% with intensive therapy (DCCT) [2]

1. Diabetic Retinopathy [38]:

Screening: Annual digital retinal photography for all T1DM (from age 12 or 5 years post-diagnosis)

2. Diabetic Nephropathy [39]:

Management:

• ACE inhibitor or ARB (renoprotective independent of BP)
• BP target less than 130/80 mmHg
• Optimize glycemic control
• SGLT2 inhibitors for renoprotection (if eGFR adequate)

3. Diabetic Neuropathy [40]:

Diabetic Foot:

• Annual foot examination: monofilament (sensation), pulses, inspection for ulcers/deformity
• Charcot neuroarthropathy: Red, hot, swollen foot (often painless); MRI for diagnosis; total contact casting
• Multidisciplinary foot team (MDFT) referral for ulcers

Macrovascular Complications

Accelerated Atherosclerosis: 2-4 fold increased risk of cardiovascular disease [41]

Risk Management:

Associated Autoimmune Conditions

Screen at diagnosis and annually [42]:

---

Psychological Aspects

Diabetes Distress

Prevalence: 20-40% of people with T1DM experience significant diabetes distress [43]

Contributing Factors:

• Constant cognitive load of self-management
• Fear of hypoglycemia
• Fear of complications
• Social stigma
• Technology burden
• Burnout from relentless demands

Recognition and Management:

• Validated screening tools (PAID, DDS)
• Acknowledge burden of living with T1DM
• Set realistic expectations
• Simplify regimens where possible (technology can help)
• Psychological support (diabetes psychologist)

Diabulimia (Eating Disorder-Diabetes Mellitus Type 1)

Definition: Intentional omission or restriction of insulin to lose weight [44]

Epidemiology: 20-40% of young women with T1DM may manipulate insulin for weight control

Clinical Clues:

• Unexplained weight loss despite adequate/increased appetite
• Persistently high HbA1c without other explanation
• Recurrent DKA
• Reluctance to be weighed
• Preoccupation with body image

Risks:

• 3-fold increased mortality
• Accelerated microvascular complications
• Recurrent DKA

Management:

• Multidisciplinary approach (diabetes team + eating disorder specialists)
• Non-judgmental, supportive care
• Avoid confrontational approach to insulin adherence
• Relaxed glycemic targets initially

---

Prognosis

Life Expectancy

• Historical: Fatal within weeks to months before insulin (1921)
• Modern era: Life expectancy reduced by approximately 10-12 years compared to general population [45]
• Improving: Gap narrowing with improved technology and complications prevention

Key Prognostic Factors

Metabolic Memory [46]

The DCCT/EDIC study demonstrated that early intensive glycemic control provides lasting protection against complications, even if control subsequently deteriorates. This "metabolic memory" or "legacy effect" emphasizes the importance of good control from diagnosis.

---

Quality Metrics

Performance Indicators

---

Patient Education

Key Messages

Understanding Your Diabetes: "Type 1 diabetes is an autoimmune condition where your immune system has destroyed the insulin-producing cells in your pancreas. You need to take insulin for the rest of your life because your body cannot make its own. This is different from Type 2 diabetes, which is mainly related to insulin resistance."

Never Stop Insulin: "Even if you are not eating or feeling unwell, you must never stop your insulin. Your body needs insulin to prevent a dangerous condition called diabetic ketoacidosis (DKA). If you are vomiting or cannot keep food down, seek medical help urgently."

Sick Day Rules: "When you are unwell, your body needs MORE insulin, not less. Check your blood glucose and ketones more frequently. If your ketones are rising or you cannot keep fluids down, contact your diabetes team or go to the emergency department."

Hypoglycemia: "If your blood sugar goes low (below 4.0), treat immediately with 15 grams of fast-acting sugar (4 jelly babies, 150 mL fruit juice). Recheck in 15 minutes and repeat if needed. Always carry glucose with you."

When to Seek Emergency Help

Call 999 or go to A&E if:

• Vomiting and unable to keep fluids down
• Blood ketones > 3.0 mmol/L
• Drowsy, confused, or losing consciousness
• Severe abdominal pain with nausea
• Difficulty breathing (fast, deep breaths)
• Unconscious or fitting (seizure) from low blood sugar

---

Key Clinical Pearls

Diagnostic Pearls

1. Ketosis at presentation strongly suggests T1DM: Even in adults, ketones + hyperglycemia = think Type 1
2. Autoantibodies confirm diagnosis in atypical cases: GAD65, IA-2, ZnT8 distinguish T1DM from T2DM
3. C-peptide assesses residual beta-cell function: Low/undetectable confirms absolute insulin deficiency
4. LADA presents as "Type 2" but is autoimmune: Suspect in slim adults with poor response to oral agents; check GAD antibodies
5. New-onset T1DM in adults is common: 50% diagnosed after age 20; don't miss it
6. HbA1c may be normal in acute-onset T1DM: Symptoms develop rapidly before chronic hyperglycemia

Treatment Pearls

7. Basal-bolus is the gold standard: MDI or pump; never use premixed insulins in T1DM
8. Carbohydrate counting enables flexible eating: DAFNE principles; insulin-to-carb ratios
9. CGM is standard of care: Offered to all T1DM (NICE NG17); dramatically improves outcomes
10. Hybrid closed-loop systems are transformative: NICE TA943 recommends for T1DM; reduces HbA1c and hypoglycemia
11. Never stop basal insulin: Even when fasting or unwell; prevents DKA
12. Sick day rules save lives: More insulin (not less) when unwell; check ketones
13. Pump failure causes rapid DKA: No long-acting insulin on board; intervene immediately
14. Lipohypertrophy causes erratic control: Inspect injection sites; rotate strictly

Complication Prevention Pearls

15. DCCT proved intensive control reduces complications: 60% reduction in microvascular disease
16. Metabolic memory means early control matters: Good control from diagnosis provides lasting protection
17. ACE inhibitor/ARB for any albuminuria: Renoprotective even if normotensive
18. Annual screening is essential: Eyes (retinal photo), kidneys (ACR, eGFR), feet (monofilament)
19. Statin for cardiovascular protection: All T1DM > 40 years or > 10 years duration
20. Screen for associated autoimmune conditions: Thyroid and coeliac disease common

---

Evidence and Guidelines

Landmark Trials

1. DCCT (Diabetes Control and Complications Trial, 1993) [2]:

• Design: RCT; intensive vs conventional insulin therapy in T1DM
• Finding: Intensive therapy (HbA1c ~7%) reduced:
  • Retinopathy by 76%
  • Nephropathy by 50%
  • Neuropathy by 60%
• Trade-off: 3-fold increased risk of severe hypoglycemia
• Legacy: Established HbA1c targets; intensive therapy as standard

2. EDIC (Epidemiology of Diabetes Interventions and Complications, 2005) [46]:

• Design: Long-term follow-up of DCCT cohort
• Finding: Early intensive control provided lasting protection ("metabolic memory")
• Impact: Emphasized importance of good control from diagnosis

3. CONCEPTT (Continuous Glucose Monitoring in Pregnant Women with T1DM, 2017) [47]:

• Design: RCT of CGM vs SMBG in pregnancy
• Finding: CGM improved neonatal outcomes (reduced LGA, NICU admission, hypoglycemia)
• Impact: CGM recommended for all T1DM pregnancies

Key Guidelines

• NICE NG17 (2015, updated 2022): Type 1 diabetes in adults - diagnosis and management [27]
• NICE TA943 (2023): Hybrid closed-loop systems for managing blood glucose in T1DM [29]
• ADA Standards of Medical Care in Diabetes (2024) [24]
• ISPAD Guidelines (2022): Management of Type 1 Diabetes in Children and Adolescents [48]

---

References

1. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6(1):40. doi:10.1038/s41572-020-0165-1

2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi:10.1056/NEJM199309303291401

3. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-1717. doi:10.1056/NEJMoa1907863

4. Usher-Smith JA, Thompson M, Ercole A, Walter FM. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia. 2012;55(11):2878-2894. doi:10.1007/s00125-012-2690-2

5. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82. doi:10.1016/S0140-6736(13)60591-7

6. Katsarou A, Gudbjörnsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. doi:10.1038/nrdp.2017.16

7. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can Med Assoc J. 1922;12(3):141-146.

8. Phillip M, Nimri R, Bergenstal RM, et al. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023;44(2):254-280. doi:10.1210/endrev/bnac022

9. Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018;6(2):122-129. doi:10.1016/S2213-8587(17)30362-5

10. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13(11):674-686. doi:10.1038/nrendo.2017.99

11. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi:10.2337/dc15-1419

12. Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741-760. doi:10.1016/S2213-8587(22)00218-2

13. Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408-417. doi:10.1007/s00125-018-4763-3

14. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98-115. doi:10.34172/hpp.2020.18

15. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep. 2011;11(6):533-542. doi:10.1007/s11892-011-0223-x

16. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331-2339. doi:10.1016/S0140-6736(16)30582-7

17. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet. 2016;387(10035):2340-2348. doi:10.1016/S0140-6736(16)30507-4

18. Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150-161. doi:10.1038/s41574-020-00443-4

19. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab. 2010;95(1):25-33. doi:10.1210/jc.2009-1365

20. Joint British Diabetes Societies for Inpatient Care. The Management of Diabetic Ketoacidosis in Adults. 2nd ed. 2013. Updated 2021.

21. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. doi:10.2337/dc09-9032

22. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395. doi:10.2337/dc12-2480

23. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25(4):501-504. doi:10.1111/j.1464-5491.2008.02413.x

24. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. doi:10.2337/dc24-S002

25. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-183. doi:10.1056/NEJMra040832

26. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med. 2012;366(17):1616-1624. doi:10.1056/NEJMct1113948

27. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. NICE guideline [NG17]. 2015. Updated 2022.

28. Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021;64(5):1007-1015. doi:10.1007/s00125-021-05391-w

29. National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance [TA943]. 2023.

30. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3-S13. doi:10.1089/dia.2015.0417

31. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002;325(7367):746. doi:10.1136/bmj.325.7367.746

32. Diabetes UK. Managing sick days. 2023. https://www.diabetes.org.uk

33. Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5(5):377-390. doi:10.1016/S2213-8587(17)30014-1

34. Richardson T, Weiss M, Thomas P, Kerr D. Day after the night before: influence of evening alcohol on risk of hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2005;28(7):1801-1802. doi:10.2337/diacare.28.7.1801

35. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. NICE guideline [NG3]. 2015. Updated 2020.

36. Driver and Vehicle Licensing Agency. Assessing fitness to drive: a guide for medical professionals. 2024.

37. Joint British Diabetes Societies for Inpatient Care. Management of adults with diabetes undergoing surgery and elective procedures. 2016.

38. Wong TY, Cheung CM, Larsen M, Sharma S, Simó R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. doi:10.1038/nrdp.2016.12

39. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116

40. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. doi:10.1038/s41572-019-0092-1

41. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843-2863. doi:10.2337/dc14-1720

42. Nederstigt C, Uitbeijerse BS, Janssen LGM, Corssmit EPM, de Koning EJP, Dekkers OM. Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019;180(2):135-144. doi:10.1530/EJE-18-0515

43. Fisher L, Polonsky WH, Hessler D. Addressing diabetes distress in clinical care: a practical guide. Diabet Med. 2019;36(7):803-812. doi:10.1111/dme.13967

44. Pinhas-Hamiel O, Hamiel U, Levy-Shraga Y. Eating disorders in adolescents with type 1 diabetes: Challenges in diagnosis and treatment. World J Diabetes. 2015;6(3):517-526. doi:10.4239/wjd.v6.i3.517

45. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015;313(1):37-44. doi:10.1001/jama.2014.16425

46. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. doi:10.1056/NEJMoa052187

47. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017;390(10110):2347-2359. doi:10.1016/S0140-6736(17)32400-5

48. Sherr JL, Tauschmann M, Engberg S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies. Pediatr Diabetes. 2022;23(8):1406-1431. doi:10.1111/pedi.13451

---

Copyright 2026 MedVellum. All rights reserved.